What is the recommended infusion rate of 20% albumin for a patient with chronic liver disease who is in shock?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Albumin Infusion Rate in Chronic Liver Disease with Shock

For patients with chronic liver disease (cirrhosis) presenting with sepsis-induced shock, administer 20% albumin at 0.5-1.0 g/kg over 3 hours as the initial resuscitation strategy.

Infusion Protocol

The FDA-approved dosing for hypovolemic shock states that 20% albumin should be administered intravenously, with the volume and speed adapted to individual patient response 1. However, the most recent high-quality evidence from the ALPS trial (2022) specifically evaluated cirrhotic patients with sepsis-induced hypotension and used 0.5-1.0 g/kg of 20% albumin infused over 3 hours 2.

Practical Administration Details

  • Dose: 0.5-1.0 g/kg of 20% albumin
  • Infusion time: 3 hours
  • Target: Mean arterial pressure (MAP) >65 mmHg
  • Maximum rate: Do not exceed 2 mL/minute in hypoproteinemic patients to avoid circulatory embarrassment and pulmonary edema 1

Evidence Supporting This Approach

The ALPS trial demonstrated that 20% albumin was superior to crystalloid (plasmalyte) in achieving MAP >65 mmHg at 3 hours (62% vs 22%; p <0.001) 2. The albumin group also showed:

  • Faster decline in arterial lactate (p = 0.03)
  • Reduced need for dialysis (48% vs 62%)
  • Longer time to dialysis initiation

Critical Safety Considerations

Monitor closely for pulmonary complications. In the ALPS trial, treatment had to be discontinued in 22% of albumin patients due to adverse effects (primarily pulmonary complications), compared to zero discontinuations in the crystalloid group 2. The 2024 CHEST guidelines also noted higher rates of pulmonary edema with albumin in cirrhotic patients with extraperitoneal infections 3.

Monitoring Requirements During Infusion

  • Respiratory status (watch for dyspnea, oxygen desaturation)
  • Hemodynamic response (MAP, heart rate)
  • Signs of fluid overload (jugular venous distension, lung crackles)
  • Arterial lactate clearance

Important Caveats

The 28-day mortality was identical between albumin and crystalloid groups (58% vs 62%, p = 0.57) in the ALPS trial 2. This means while albumin achieves faster hemodynamic stabilization, it does not improve survival and carries higher risk of pulmonary complications.

When to Consider Alternative Approaches

  • If patient has pre-existing pulmonary edema or volume overload
  • If patient cannot tolerate close monitoring for respiratory complications
  • In resource-limited settings where crystalloid may be safer and better tolerated 2

Infusion Rate Considerations

A 2022 study in volunteers found that fast infusion (over 30 minutes) versus slow infusion (over 120 minutes) of 20% albumin showed no disadvantages of the higher rate, with longer intravascular persistence of albumin with faster administration 4. However, in the shock setting with cirrhosis, the 3-hour infusion protocol from the ALPS trial represents the evidence-based standard 2.

Preparation

  • Use only 16-gauge needles for vial sizes 20 mL or larger
  • Can be administered undiluted or diluted in 0.9% sodium chloride or 5% dextrose
  • If sodium restriction required, use 5% dextrose only 1

Bottom line: Administer 0.5-1.0 g/kg of 20% albumin over 3 hours for cirrhotic patients in septic shock, but maintain heightened vigilance for pulmonary complications that may necessitate treatment discontinuation.

References

Related Questions

Is a group and hold and cross-match required for transfusing albumin 20% (twenty percent albumin solution)?
What is the recommended dosage and administration rate of albumin 20% for a patient with hypoalbuminemia, considering their volume status, cardiac function, and renal function?
What is the appropriate infusion rate and monitoring for a 25% albumin solution containing 50 g in 200 mL administered over 30 minutes?
Can albumin infusion in patients with cirrhosis cause pulmonary edema?
In a 53-year-old man with alcoholic cirrhosis presenting with abdominal pain, ascitic fluid polymorphonuclear leukocyte count 270 cells/µL, fever, tachycardia, hypotension (blood pressure 90/55 mmHg), bilateral lower‑extremity edema and bilateral lung crackles, should the next step be cefotaxime alone or cefotaxime combined with intravenous albumin?
In a patient with extensive, refractory hidradenitis suppurativa involving the perineal/perianal region who is a surgical candidate, should fecal diversion (temporary loop colostomy) be performed prior to definitive surgery?
What is the recommended management for acute silicoproteinosis?
Can I travel by air after a pulmonary embolism provoked by a prior flight, and what anticoagulation regimen and precautions are needed?
Why is furosemide (loop diuretic) not recommended in patients with severe renal failure (eGFR <30 mL/min/1.73 m²)?
What does a low prothrombin time indicate in a child and how should it be evaluated?
What glucocorticoid dose should be used to treat serum sickness?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.